Abstract【Objective】To investigate the efficacy of Irinotecan combined with bevacizumab in the treatment of platinum-resistant recurrent ovarian cancer. 【Methods】A total of 118 patients with platinum-resistant recurrent ovarian cancer treated in our hospital from Sep. 2016 to Sep. 2018 were randomly divided into the control group and the observation group with 59 cases in each group. The control group was treated with Irinotecan, while the observation group was treated with Irinotecan combined with bevacizumab. The short-term efficacy, serum tumor markers such as human epididymal secretory protein 4 (HE4), carbohydrate antigen 125 (CA125) and carcinoembryonic antigen (CEA), long-term efficacy and adverse reactions of the two groups were compared. 【Results】 After treatment, the objective remission rate (ORR) in the observation group was significantly higher than that in the control group (57.63% vs 37.29%, P<0.05). The levels of HE4,CA125, and CEA in both groups were lower than those before treatment, and those in the observation group were significantly lower than those in the control group (P<0.05). The total survival time (OS) and progression-free survival (PFS) of patients in the observation group were significantly longer than those in the control group (P<0.05). The incidence of hemoglobin decrease, renal function damage, alanine aminotransferase increase, central granulocyte decrease, thrombocytopenia, and peripheral neuritis in the two groups were compared (P>0.05). The incidence of grade 0 leukopenia in the observation group was significantly higher than that in the control group (P<0.05). The incidence of grade Ⅲ-Ⅳ diarrhea and nausea and vomiting in the observation group was significantly lower than that in the control group (P<0.05). 【Conclusion】Irinotecan combined with bevacizumab is effective in the treatment of platinum-resistant recurrent ovarian cancer. It can also improve PFS and OS in patients with platinum-resistant ovarian cancer, and the adverse reactions are tolerable. It is worthy of clinical application.
SUN Zi-qin,CHENG Xian-ying. Therapeutic Effect of Irinotecan Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Cancer[J]. JOURNAL OF CLINICAL RESEARCH, 2020, 37(12): 1782-1785.
2020, Vol. 37 
